A randomized, double blind research study to see what effect the investigational drug, pridopidine, has on movement, thinking, and behavior, compared to placebo (a capsule that looks like pridopidine but has no active ingredient), in people with Huntington disease after 26 weeks of receiving either pridopidine or placebo.
What is the Pride-HD Study?
The purpose of this randomized, double blind study is to see what effect the investigational drug, pridopidine, has on movement, thinking, and behavior, compared to placebo, in people with Huntington disease after 26 weeks of receiving either pridopidine or placebo. In addition, information will be collected about safety and tolerability of pridopidine in people with HD.
Who is running the Pride-HD Trial?
Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington Disease Network (EHDN). 400 participants will be enrolled globally at approximately 51 study sites. Participants will receive either pridopidine or placebo for 26 weeks.
The study is sponsored by Teva Branded Pharmaceutical Products.
Who is eligible to participate in the Pride-HD trial?
You may be eligible to participate in the study if you meet the following requirements:
You are over the age of 21
Have a diagnosis of Huntington disease
Have a caregiver willing to attend study visits with you
Have no history of significant heart disease, epilepsy or seizures within the last 5 years, or serious medical illness
Have not been treated with tetrabenazine within 6 weeks of study screening.
How can I learn more about the Pride-HD trial?